tiprankstipranks
Advertisement
Advertisement

BHVN Stock Latest News

Biohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures
Company AnnouncementsBiohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures
4h ago
BHVN
Biohaven Expands At-The-Market Equity Offering Program
PremiumCompany Announcements
Biohaven Expands At-The-Market Equity Offering Program
12h ago
8K
BHVN
Biohaven: Buy Rating Reiterated as Analyst Sees Multiple Pipeline Catalysts and Maintains $21 Price Target
PremiumRatings
Biohaven: Buy Rating Reiterated as Analyst Sees Multiple Pipeline Catalysts and Maintains $21 Price Target
21h ago
BHVN
Biohaven price target lowered to $22 from $23 at RBC Capital
PremiumThe Fly
Biohaven price target lowered to $22 from $23 at RBC Capital
22h ago
BHVN
Biohaven price target lowered to $12 from $14 at BofA
PremiumThe Fly
Biohaven price target lowered to $12 from $14 at BofA
1d ago
BHVN
Biohaven: Buy Rating Reiterated as Pipeline De‑Risking Builds Ahead of Key 2026 Readouts; $30 Price Target Maintained
PremiumRatingsBiohaven: Buy Rating Reiterated as Pipeline De‑Risking Builds Ahead of Key 2026 Readouts; $30 Price Target Maintained
1d ago
BHVN
Biohaven Price Target Trimmed to $12 as Analyst Maintains Hold Amid Balanced Pipeline Upside and Financing Risks
Premium
Ratings
Biohaven Price Target Trimmed to $12 as Analyst Maintains Hold Amid Balanced Pipeline Upside and Financing Risks
1d ago
BHVN
Biohaven Shareholders Back Board, Auditor and Executive Pay
Premium
Company Announcements
Biohaven Shareholders Back Board, Auditor and Executive Pay
2d ago
8K
BHVN
Biohaven files automatic mixed securities shelf
PremiumThe Fly
Biohaven files automatic mixed securities shelf
2d ago
BHVN
Biohaven reports Q1 adjusted EPS (69c), consensus (76c)
PremiumThe Fly
Biohaven reports Q1 adjusted EPS (69c), consensus (76c)
2d ago
BHVN
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
PremiumThe Fly
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
23d ago
DYN
RNA
Biohaven initiated with a Buy at Canaccord
PremiumThe Fly
Biohaven initiated with a Buy at Canaccord
23d ago
BHVN
Biohaven price target raised to $17 from $14 at Citi
PremiumThe FlyBiohaven price target raised to $17 from $14 at Citi
1M ago
BHVN
Biohaven completes enrollment in Phase 2 study on taldefgrobep alfa
Premium
The Fly
Biohaven completes enrollment in Phase 2 study on taldefgrobep alfa
2M ago
BHVN
Biohaven price target raised to $30 from $15 at TD Cowen
Premium
The Fly
Biohaven price target raised to $30 from $15 at TD Cowen
2M ago
BHVN
Biohaven price target raised to $27 from $24 at Goldman Sachs
PremiumThe Fly
Biohaven price target raised to $27 from $24 at Goldman Sachs
2M ago
BHVN
XENE
Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate
PremiumThe Fly
Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate
2M ago
BHVN
XENE
Biohaven fractionally lower after Xenon reports azetukalner Phase 3 hit target
PremiumThe Fly
Biohaven fractionally lower after Xenon reports azetukalner Phase 3 hit target
2M ago
BHVN
XENE
Controversial Prasad leaving FDA, NYT reports
PremiumThe Fly
Controversial Prasad leaving FDA, NYT reports
2M ago
AZN
BMY
Biohaven price target lowered to $10 from $11 at H.C. Wainwright
PremiumThe FlyBiohaven price target lowered to $10 from $11 at H.C. Wainwright
2M ago
BHVN
Biohaven price target lowered to $14 from $15 at BofA
Premium
The Fly
Biohaven price target lowered to $14 from $15 at BofA
2M ago
BHVN
Maintaining Hold on Biohaven: Encouraging Early Signals but Awaiting Placebo-Controlled Data and Funding Clarity
Premium
Ratings
Maintaining Hold on Biohaven: Encouraging Early Signals but Awaiting Placebo-Controlled Data and Funding Clarity
2M ago
BHVN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >